Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.

Shang N, Wang H, Bank T, Perera A, Joyce C, Kuffel G, Zilliox MJ, Cotler SJ, Ding X, Dhanarajan A, Breslin P, Qiu W.

Hepatology. 2019 May 9. doi: 10.1002/hep.30707. [Epub ahead of print]

PMID:
31069844
2.

Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic.

Malespin M, Harris C, Kanar O, Jackman K, Smotherman C, Johnston A, Ferm J, de Melo SW Jr, Scolapio JS, Nelson DR, Cotler SJ.

Ann Hepatol. 2019 Mar - Apr;18(2):304-309. doi: 10.1016/j.aohep.2018.06.001. Epub 2019 Apr 12.

3.

Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler SJ, Major M, Dahari H.

Vaccine. 2019 May 1;37(19):2608-2616. doi: 10.1016/j.vaccine.2019.02.081. Epub 2019 Apr 5.

PMID:
30962092
4.

American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults.

Kallwitz ER, Tayo BO, Kuniholm MH, Cai J, Daviglus M, Cooper RS, Cotler SJ.

Clin Gastroenterol Hepatol. 2019 Feb 8. pii: S1542-3565(19)30145-4. doi: 10.1016/j.cgh.2019.02.007. [Epub ahead of print]

PMID:
30743004
5.

Correction: Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Eliav MC, Skorochod Y, Breuer GS, Tur-Kaspa R, Wiener YW, Stern A, Cotler SJ, Dahari H, Lurie Y.

PLoS One. 2019 Feb 7;14(2):e0212252. doi: 10.1371/journal.pone.0212252. eCollection 2019.

6.

A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ.

Antiviral Res. 2019 Mar;163:149-155. doi: 10.1016/j.antiviral.2019.01.017. Epub 2019 Jan 31.

PMID:
30711416
7.

Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.

Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y.

PLoS One. 2019 Jan 15;14(1):e0210173. doi: 10.1371/journal.pone.0210173. eCollection 2019. Erratum in: PLoS One. 2019 Feb 7;14(2):e0212252.

8.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2019 May;39(5):826-834. doi: 10.1111/liv.14014. Epub 2018 Dec 28.

PMID:
30499631
9.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

10.

Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.

Wang F, Bank T, Malnassy G, Arteaga M, Shang N, Dalheim A, Ding X, Cotler SJ, Denning MF, Nishimura MI, Breslin P, Qiu W.

Hepatol Commun. 2018 Apr 17;2(6):732-746. doi: 10.1002/hep4.1181. eCollection 2018 Jun.

11.

Gender disparities in liver transplant candidates with nonalcoholic steatohepatitis.

Loy VM, Joyce C, Bello S, VonRoenn N, Cotler SJ.

Clin Transplant. 2018 Aug;32(8):e13297. doi: 10.1111/ctr.13297. Epub 2018 Jul 19.

PMID:
29804305
12.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

13.

Studies on the Tissue Localization of HKDC1, a Putative Novel Fifth Hexokinase, in Humans.

Khan MW, Ding X, Cotler SJ, Clarke M, Layden BT.

J Histochem Cytochem. 2018 May;66(5):385-392. doi: 10.1369/0022155418756849. Epub 2018 Feb 5.

14.

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K.

PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.

15.

Associations of Insulin Resistance and Glycemia With Liver Enzymes in Hispanic/Latino Youths: Results From the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth).

Parrinello CM, Rudolph BJ, Lazo M, Gallo LC, Thyagarajan B, Cotler SJ, Qi Q, Seeherunvong T, Vidot DC, Strickler HD, Kaplan RC, Isasi CR.

J Clin Gastroenterol. 2019 Feb;53(2):e46-e53. doi: 10.1097/MCG.0000000000000946.

PMID:
29099463
16.

Case Series of 10 Patients with Cirrhosis Undergoing Emergent Repair of Ruptured Umbilical Hernias: Natural History and Predictors of Outcomes.

Malespin M, Moore CM, Fialho A, de Melo SW Jr, Benyashvili T, Kothari AN, di Sabato D, Kallwitz ER, Cotler SJ, Lu AD.

Exp Clin Transplant. 2019 Apr;17(2):210-213. doi: 10.6002/ect.2017.0086. Epub 2017 Jul 11.

17.

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H.

Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.

18.

End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals.

Shteyer E, Dahari H, Gafanovich I, Dery I, Wolf D, Cotler SJ, Lurie Y.

Therap Adv Gastroenterol. 2017 May;10(5):429-430. doi: 10.1177/1756283X17694808. Epub 2017 Feb 1. No abstract available.

19.

Adverse Effect of Post-Discharge Care Fragmentation on Outcomes after Readmissions after Liver Transplantation.

Kothari AN, Loy VM, Brownlee SA, Ezure Y, Schaidle-Blackburn C, Cotler SJ, di Sabato D, Kuo PC, Lu AD.

J Am Coll Surg. 2017 Jul;225(1):62-67. doi: 10.1016/j.jamcollsurg.2017.03.017. Epub 2017 Apr 9.

PMID:
28400298
20.

Early Hospital Readmissions and Mortality in Patients With Decompensated Cirrhosis Enrolled in a Large National Health Insurance Administrative Database.

Scaglione SJ, Metcalfe L, Kliethermes S, Vasilyev I, Tsang R, Caines A, Mumtaz S, Goyal V, Khalid A, Shoham D, Markossian T, Luke A, Underwood H, Cotler SJ.

J Clin Gastroenterol. 2017 Oct;51(9):839-844. doi: 10.1097/MCG.0000000000000826.

PMID:
28383303
21.

Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites.

Venepalli NK, Modayil MV, Berg SA, Nair TD, Parepally M, Rajaram P, Gaba RC, Bui JT, Huang Y, Cotler SJ.

World J Hepatol. 2017 Mar 8;9(7):391-400. doi: 10.4254/wjh.v9.i7.391.

22.

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.

23.

Hepatitis B Stigma and Knowledge among Vietnamese in Ho Chi Minh City and Chicago.

Dam L, Cheng A, Tran P, Wong SS, Hershow R, Cotler S, Cotler SJ.

Can J Gastroenterol Hepatol. 2016;2016:1910292. doi: 10.1155/2016/1910292. Epub 2016 Dec 22.

24.

The time and cost investment required to obtain and initiate direct-acting antiviral therapy.

Loy V, Benyashvili T, Adams W, Pavkov D, O'Mahoney M, Cotler SJ.

Antivir Ther. 2016;21(8):731-733. doi: 10.3851/IMP3068. Epub 2016 Jul 14.

PMID:
27414001
25.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

World J Hepatol. 2016 Jul 18;8(20):858-62. doi: 10.4254/wjh.v8.i20.858.

26.

Resurrection of response-guided therapy for sofosbuvir combination therapies.

Dahari H, Halfon P, Cotler SJ.

J Hepatol. 2016 Sep;65(3):462-4. doi: 10.1016/j.jhep.2016.05.028. Epub 2016 May 27. No abstract available.

27.

An assessment of racial differences in the upper limits of normal ALT levels in children and the effect of obesity on elevated values.

Kliethermes S, Ma M, Purtell C, Balasubramanian N, Gonzalez B, Layden TJ, Cotler SJ.

Pediatr Obes. 2017 Oct;12(5):363-372. doi: 10.1111/ijpo.12152. Epub 2016 May 30.

PMID:
27237782
28.

FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.

Shang N, Arteaga M, Zaidi A, Cotler SJ, Breslin P, Ding X, Kuo P, Nishimura M, Zhang J, Qiu W.

Gene Expr. 2016;17(1):79-88. doi: 10.3727/105221616X691604. Epub 2016 May 2.

29.

Inhibition of SIRT2 suppresses hepatic fibrosis.

Arteaga M, Shang N, Ding X, Yong S, Cotler SJ, Denning MF, Shimamura T, Breslin P, Lüscher B, Qiu W.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1155-68. doi: 10.1152/ajpgi.00271.2015. Epub 2016 Apr 28.

30.

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer.

Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH.

BMC Gastroenterol. 2016 Feb 29;16:30. doi: 10.1186/s12876-016-0432-5.

31.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.

32.

Cure prevents more than transmission of hepatitis C virus.

Dahari H, Cotler SJ, Feld JJ.

Hepatology. 2016 Sep;64(3):1003-4. doi: 10.1002/hep.28449. Epub 2016 Mar 7. No abstract available.

33.

Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.

Duarte-Rojo A, Fischer SE, Adeyi O, Zita D, Deneke MG, Selzner N, Chen L, Malespin M, Cotler SJ, McGilvray ID, Feld JJ.

J Viral Hepat. 2016 May;23(5):340-7. doi: 10.1111/jvh.12494. Epub 2015 Dec 29.

PMID:
26710754
34.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.

35.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16.

36.

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E, Lurie Y.

Liver Int. 2015 Feb;35(2):289-94. doi: 10.1111/liv.12692. Epub 2014 Oct 10.

37.

Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage.

Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH, Chen J, Gouskova N, Pirzada A, Talavera GA, Youngblood ME, Cotler SJ.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):569-76. doi: 10.1016/j.cgh.2014.08.037. Epub 2014 Sep 15.

38.

FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W.

Hepatology. 2015 Jan;61(1):214-26. doi: 10.1002/hep.27402. Epub 2014 Nov 25.

39.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.

Hepatology. 2014 Dec;60(6):1902-10. doi: 10.1002/hep.27357. Epub 2014 Oct 27.

40.

Presurgical transarterial chemoembolization does not increase biliary stricture incidence in orthotopic liver transplant patients.

Casadaban L, Malespin M, Cheung A, McGuffey RA, Boulay BR, Halline AG, Brown RD, Cotler SJ, Jeon H, Bui JT, Gaba RC.

Transplant Proc. 2014 Jun;46(5):1413-9. doi: 10.1016/j.transproceed.2014.03.012.

PMID:
24935306
41.

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H.

Antivir Ther. 2015;20(2):149-55. doi: 10.3851/IMP2806. Epub 2014 Jun 10.

42.

Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Layden JE, Tayo BO, Cotler SJ, Clark NM, Baraoidan K, Friedman SL, Cooper RS.

Transplantation. 2014 May 27;97(10):1072-8. doi: 10.1097/01.TP.0000440953.06886.a3.

43.

Prevalence and correlates of suspected nonalcoholic fatty liver disease in Chinese American children.

Malespin M, Sleesman B, Lau A, Wong SS, Cotler SJ.

J Clin Gastroenterol. 2015 Apr;49(4):345-9. doi: 10.1097/MCG.0000000000000121.

PMID:
24667593
44.

Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach.

Dahari H, Cotler SJ.

Hepatology. 2014 Jun;59(6):2422-3. doi: 10.1002/hep.26772. Epub 2014 Apr 14. No abstract available.

45.

Biomechanics and functionality of hepatocytes in liver cirrhosis.

Sun S, Song Z, Cotler SJ, Cho M.

J Biomech. 2014 Jun 27;47(9):2205-10. doi: 10.1016/j.jbiomech.2013.10.050. Epub 2013 Nov 8.

PMID:
24262849
46.

Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients.

Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Von Roenn NM, Berkes JL, Cotler SJ.

Ann Hepatol. 2013 Sep-Oct;12(5):766-73.

47.

Physical activity and metabolic syndrome in liver transplant recipients.

Kallwitz ER, Loy V, Mettu P, Von Roenn N, Berkes J, Cotler SJ.

Liver Transpl. 2013 Oct;19(10):1125-31. doi: 10.1002/lt.23710. Epub 2013 Aug 15.

48.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.

49.

Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.

Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, Berkes JL, Cotler SJ.

J Vasc Interv Radiol. 2013 Mar;24(3):411-20, 420.e1-4; quiz 421. doi: 10.1016/j.jvir.2012.10.026. Epub 2013 Jan 9.

PMID:
23312989
50.

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.

Dahari H, Cotler SJ, Layden TJ, Perelson AS.

J Hepatol. 2013 Apr;58(4):840-2. doi: 10.1016/j.jhep.2012.08.029. Epub 2012 Dec 13. No abstract available.

Supplemental Content

Loading ...
Support Center